Previous Article | Next Article ![]()
Molecular and Cellular Biology, September 2004, p. 8134-8144, Vol. 24, No. 18
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.18.8134-8144.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Emerson Liu,1,
Sumita Sinha,1 Stuart Cook,2 David S. Milstone,3 Calum A. MacRae,2 Massimo Mariotti,2 Peter J. Kuhlencordt,4 Thomas Force,5 Anthony Rosenzweig,2 Rene St-Arnaud,6 Shoukat Dedhar,7 and Robert E. Gerszten1,2*
Center for Immunology and Inflammatory Diseases,1 Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, and Harvard Medical School, Boston,2 Vascular Research Division, Department of Pathology, Brigham and Women's Hospital,3 Molecular Cardiology Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts,5 Department of Medicine, Julius-Maximilians-Universität, Würzburg, Germany,4 Shriners Hospital and McGill University, Montreal, Quebec, Canada,6 Department of Biochemistry and Molecular Biology, University of British Columbia, and BC Cancer Agency, Jack Bell Research Centre at Vancouver General Hospital and Health Service Center, Vancouver, British Columbia, Canada7
Received 18 February 2004/ Returned for modification 28 March 2004/ Accepted 30 May 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Integrins are a family of heterodimeric (
ß) transmembrane cell surface receptors that mediate cell-cell adhesion as well as cell-matrix contacts (4, 5, 14, 24). Integrin-ligand interactions transduce signals that modulate the migration, proliferation, differentiation, and survival of cells. Signals originating from within the cell, in turn, can influence the avidity or affinity of integrins for their extracellular ligands. Recent data from several lines of investigation suggest that integrin-Linked kinase (ILK) is a crucial binding partner of integrins (11, 23, 34). ILK is a highly conserved serine/threonine protein kinase with pleckstrin homology and ankyrin repeat domains. ILK was identified in a yeast two-hybrid screen by virtue of its interaction with the cytoplasmic domain of ß1 integrins (23). ILK also interacts with critical actin-binding proteins, such as paxillin, CH-ILKBP, and affixin via its C-terminal kinase domain and with the Lim-domain-only proteins, PINCH1 and -2, via its first ankyrin domain (41). Several in vitro studies have suggested that ILK confers key survival signals via its ability to phosphorylate and activate Akt/protein kinase B (12, 32, 38). ILK also plays a critical structural role in the formation of integrin adhesion complexes. From a functional perspective, overexpression of ILK in epithelial cells confers anchorage-independent cell growth and tumorigenicity in nude mice, and several human tumors, including melanoma, ovarian cancer, and prostate cancer, have marked overexpression of ILK (1, 10, 19). ILK has also been implicated in the adhesion of leukocytes (15).
To address more definitively the physiological role of ILK in vivo, investigators have turned to genetic models. Deletion of ILK in Caenorhabditis elegans leads to embryonic demise that resembles the phenotype of ß-integrin knockouts (27). Similarly, complete knockout in mice confers peri-implantation lethality, since ILK is critical for epiblast polarization (34). More recent studies have shown that tissue-specific deletion of ILK in chondrocytes leads to abnormalities in bone proliferation and dwarfism (20, 37). For the present studies, we employed both the Cre-lox system with mice to specifically evaluate the role of ILK in endothelial biology and antisense technology with zebra fish to study the effects of global deficiency on vascular development. In vivo and in purified endothelial cells, we found a critical role for ILK in vascular development and in integrin-matrix interactions and cell survival. The effects of ILK in these pathways may have important implications for both endothelial cell homeostasis and vascular pathology.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Murine system. We employed a recently generated mouse strain carrying a LoxP-flanked (floxed) ILK gene (ILKflox/flox) which has been previously described in detail (37, 38). To delete ILK in vivo in endothelial cells, ILKflox/flox mice were bred to transgenic mice expressing Cre recombinase under the direction of the tyrosine kinase Tek (Tie2) promoter/enhancer (Tie2-Cretg/+), which provides expression in endothelial cells during embryogenesis and adulthood (25).
Genotype determination for Tie2-Cre transgene and ILK alleles. Gene and transgene designations are followed by genotype information in superscript text. Superscript plus and flox indicate wild-type and floxed alleles, respectively. In Tie2-Cre transgenic mice, superscript tg and plus indicate presence and absence (wild type), respectively, of the transgene. DNA was obtained from digested tails of adult mice and from yolk sacs of dissected embryos. Inheritance of the Tie2-Cre transgene was determined by PCR using the following primers: forward, 5'-GGTCGATGCAACGAGTGATGAGGT-3'; reverse, 5'-CAGCATTGCTGTCACTTGGTCGTG-3'. ILK genotype was determined by PCR using two primers, 5'-CCAGGTGGCAGAGGTAAGTA-3' and 5'-CAAGGAATAAGGTGAGCTTCAGAA-3', for simultaneous detection of wild-type, floxed, and Cre-recombined alleles. The respective product sizes were 1.9 kb, 2.1 kb, and 230 bp. DNAs were amplified for 35 cycles (94°C for 45s, 55°C for 45s, 72°C for 2 min) in a thermal cycler.
Analysis of embryos. Timed matings were set up between male Tie2-Cretg/+:ILKwt/flox mice and female mice either homozygous or heterozygous for the ILK-floxed allele. Embryos and placentae were harvested between embryonic day 9.5 (E9.5) and E12.5, fixed in paraformaldehyde in phosphate-buffered saline (2% [vol/vol]) at 4°C for 2 h, and transferred to phosphate-buffered saline. Embryos were photographed, and embryos and placentae were embedded in paraffin, sectioned (6 µm), and stained with hematoxylin and eosin. Yolk sacs were assessed by whole-mount PECAM immunostaining using a purified anti-CD31 antibody (Pharmingen).
Zebra fish.
All experiments were performed with the Top Longfin zebra fish strain. Embryos obtained from natural spawnings were raised and maintained as described previously (39). Embryos were staged according to morphological criteria (somite number) and by timing in hours postfertilization. Transgenic lines expressing green coral fluorescent protein (GCFP) under the control of the flk-1 promoter [TG (flk1:GCFP)] were used to visualize vasculogenesis and embryonic angiogenesis (9). The cDNA of the zebra fish ortholog of ILK-1 was cloned, and antisense morpholino oligonucleotides were designed against the splice donor sequences of exon 1. Morpholinos (Gene Tools, LLC), received as sterile salt-free lyophilized solids, were resuspended in sterile water to a concentration of 1 mM. For injections, this stock solution was diluted to 120 uM with 1x Daniau's solution [58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 0.5 mM HEPES (pH 7.6)] and injected in a volume of
5 nl. The morpholino sequence was 5'-ATGCACTCACCCCTGGTTTAGGTC-3'. Morpholinos were injected into one-cell-stage zebra fish embryos at the yolk/cytoplasm interface, using a Narishige micromanipulator connected to a pressure injector (Eppendorf).
Isolation and culture of primary murine endothelial cells. Primary endothelial cells were isolated and purified from the lungs of ILKflox/flox mice and wild-type littermates as previously described (16, 17). This protocol employed a two-step magnetic bead (Dynabead M-450, Dynal Corp.) purification with rat anti-mouse ICAM-2 and PECAM-1 antibody (Pharmingen). Cells were typically >92% pure as assessed by flow cytometry for CD31 (data not shown).
Recombinant adenoviruses and endothelial cell transduction.
The adenoviruses carrying wild-type ILK (15), as well as the adenovirus control (AdGFP) (30), constitutively active Akt (Admyr-Akt) (30), and Cre recombinase (AdCre) (2) constructs have all been described previously in detail. Endothelial cells grown to
70% confluence on 0.1% gelatin-coated six-well plates were transfected with the indicated adenovirus construct at various concentrations in 500 µl of complete medium for 4 h at 37°C, and the volume was then replaced with 2 ml of fresh complete medium. Transfections were carried out for a total of 96 h. For rescue experiments, endothelial cells were transfected with various adenovirus constructs for 4 h prior to cotransfection with AdGFP or AdCre as described above.
Antibodies. Studies employed antibodies to ILK (Upstate Biotechnology), Cre (Novagen), phospho-Akt (S473), and total Akt (both from Cell Signaling), phospho-Akt (T308) (Biomol), phospho-c-Jun N-terminal kinase (Cell Signaling), phospho-glycogen synthase kinase 3 (phospho-GSK-3) and total GSK-3 (both from Cell Signaling), phospho-extracellular signal-regulated kinases 1 and 2 (Erk 1/2) (Cell Signaling), total Erk 1/2 (Santa Cruz), and beta actin (Abcam). For flow cytometry analysis, we used antibodies to CD31 (Pharmingen), active ß-1 integrin (clone 9EG7; Pharmingen), total ß1 integrin (anti-CD29; Pharmingen), total ß3 integrin (anti-CD61; Pharmingen), and the corresponding isotype-matched controls (all from Pharmingen). For immunostaining we employed F-actin phalloidin (Molecular Probes) and antivinculin (Sigma) in conjunction with an Alexa-conjugated secondary antibody.
Western blotting and Akt kinase assay. Western analysis employing the indicated antibody was performed as previously described in detail (15, 30). Akt kinase activity was assessed using a nonradioactive assay kit (no. 9840; Cell Signaling) according to the manufacturer's instructions. Samples were analyzed by Western blotting using an antibody specific for the sites phosphorylated by Akt on the substrate peptide (anti-phospho-GSK-3 S21/S9).
Apoptosis assays. Endothelial cell apoptosis was assessed by cell death detection enzyme-linked immunosorbent assay (ELISA) measuring cytoplasmic histone-associated DNA fragmentation (kit no. 1544675; Roche), by Western blot analysis for caspases 3, 8, and 9 (Cell Signaling), and by Hoechst staining (33342; Molecular Probes) according to the manufacturers' instructions. Assays were performed in the presence of serum and mitogens as described previously (16, 17).
Flow-cytometric analysis. Endothelial cells were harvested by gentle scraping in their culture media and washed once with assay buffer (1x DPBS without Ca2+ and Mg2+-1% fetal bovine serum, 400 g, 5 min, room temperature). Cells were resuspended in 100 µl of assay buffer and blocked with serum (1:10) for 5 min at room temperature. For analysis of the ß1 integrin activation state, cells were equilibrated with the indicated antibody for 5 min in the incubator (37°C, 5% CO2), followed by a 5-min period with or without manganese stimulation (Mn at 2 mM). Reactions were stopped by addition of 3 ml of ice-cold assay buffer followed by a second wash in the same volume. Cells were then stained with the indicated primary and secondary antibodies in blocking buffer and fixed in 3% paraformaldehyde, and flow cytometry was performed using a Becton Dickinson FACSCalibur set to detect fluorescence, forward scatter, and side scatter.
Confocal microscopy. Endothelial cells were washed once with 1x DPBS with Ca2+ and Mg2+ and fixed with 3.7% formaldehyde in DPBS for 10 min at room temperature. Monolayers were permeabilized for 5 min with 0.1% Triton X-100 at room temperature and blocked for 30 min at 37°C with blocking buffer (1% bovine serum albumin in DPBS). Following incubation with the indicated primary and secondary antibodies, cells were washed with DPBS and examined with a Nikon TE300 inverted fluorescence microscope fitted with a Bio-Rad 1024 confocal laser.
Statistical analysis. Data are expressed as means ± standard deviations. Statistical comparison of means was performed by using the two-tailed unpaired Student t test. The null hypothesis was considered to be rejected at P values of <0.05.
| RESULTS |
|---|
|
|
|---|
2 analysis). Subsequent analysis revealed that viable Tie2-Cretg/+:ILKflox/flox embryos were present at midgestation but displayed marked overall growth retardation by E9.5 (Fig. 1A), which coincides temporally with expected Tie2 promoter/enhancer-driven Cre expression in the embryo (13). Because vascularization of the placental labyrinth is a critical determinant of continued fetal development at this stage, we postulated that gross retardation resulted from failure of chorioallantoic placental circulation (21, 33). Examination of wild-type E9.5 placentae revealed chorioallantoic apposition, well-formed umbilical vessels, and the presence of major placental tissue layers (decidua, trophoblast giant cells, spongiotrophoblast, and chorionic epithelium). However, placentae of Tie2-Cretg/+:ILKflox/flox mice had much smaller chorioallantoic plates and greatly diminished labyrinthine vasculature, with a more than sevenfold diminution of organized endothelial-cell-lined vascular networks (Fig. 1B). We did not observe the normally robust allantoic vessel extension into the chorion or significant branching morphogenesis of chorionic epithelium in placentae of Tie2-Cretg/+:ILKflox/flox mice. Taken together, these observations indicated that ILK deficiency in fetal endothelium leads to ineffective allantoic vessel-chorion interaction, failed branching morphogenesis of chorionic epithelium, and placental labyrinth insufficiency. Similarly, there was a striking failure of yolk sac vascularization evident by E10.5, in which the fine network of branching capillaries was entirely absent (Fig. 1C), resulting in extreme friability of tissues. Finally, there appeared to be pleiotropic effects of ILK deficiency in the embryos themselves. The major axial vasculature, including the dorsal aortae, cardinal veins, and their branches, was abnormal. Vessels were smaller and fewer in number seen in the context of disorganized surrounding tissue (Fig. 1D). Notable was the incomplete closure of the neural tube in multiple ILK-deficient mutants; however, whether this represents a primary defect in the embryo or occurs as a consequence of the placental/yolk sac abnormalities remains to be defined. Together these abnormalities resulted in embryonic demise and resorption by approximately E11.5 to 12.5.
|
|
|
|
|
4-fold increase of DNA fragmentation in endothelial cells lacking ILK, compared to results with uninfected and control AdGFP-transduced cells (Fig. 6A). Furthermore, we saw a dose-dependent increase in the cleavage product of caspase 3 using Western blot analysis (Fig. 6B). Interestingly, analysis upstream of caspase 3 revealed that cell death was associated with activation of caspase 9 (Fig. 6C), the apical caspase in mitochondrial apoptosis, but not caspase 8 (not shown), the proximal caspase in death receptor-mediated apoptosis. Multiple analyses of ILK-deficient cells by using Hoechst, annexin V, and propidium iodide staining reveal that approximately 16 to 25% are apoptotic 96 h after transduction with AdCre. This range is comparable to what we observe following 6 h of cycloheximide treatment (40 µcg/ml, 6 h, 37°C), a commonly used trigger of cell death (data not shown). Importantly, transfection of wild-type endothelial cells with AdCre did not lead to any changes in cell survival (Fig. 6A and B) or to structural changes (data not shown).
|
|
|
| DISCUSSION |
|---|
|
|
|---|
vß3,
vß5, and
5ß1 are all important regulators of endothelial cell function and survival (4, 5, 14, 24). ILK was originally described for its ability to bind the carboxyl tail of ß1 and ß3 integrins (23). Our studies, using an available murine integrin activation epitope reagent, show that the activation state of ß1 integrins was consistently downregulated in ILK-deficient cells. Our working hypothesis is that loss of endothelial cell adhesion to the extracellular matrix leads to the induction of apoptosis specifically through activation of caspase 9. Recently, investigators have also described a process known as "integrin-mediated death" in which unligated integrins promote apoptosis through membrane recruitment of caspases (7). ILK might play a role in such a process as well, though our findings would suggest involvement of mitochochondrial or stress-induced pathways. Importantly, angiogenesis inhibitors, such as endostatin and tumstatin, have been shown to function by inhibiting integrin function and signaling (28, 29). Assessment of the effects of endothelium-specific ILK deletion in adult mice in vivo, particularly in the context of tumor angiogenesis, will likely be a fruitful avenue for in vestigation. Indeed, recent studies employing a biochemical inhibitor of ILK activity show inhibition of prostate tumor angiogenesis and suppression of tumor growth (36).
As noted above, endothelial cells lacking ILK had marked disruption of stress fibers and accumulated F-actin aggregates at the plasma membrane. Focal adhesions were also perturbed, as evidenced by abnormal vinculin staining. These cytoskeletal abnormalities we observed could have further hindered ß1 integrin activation by diminishing integrin clustering and avidity. ILK may play a critical role in actin organization via its interactions with
- and ß-parvin, which are members of a new family of actin binding proteins which have been shown to be important in the formation of focal adhesion and stress fibers in in vitro systems (31). ILK can also bind paxillin, which interacts with the focal adhesion protein vinculin. More recently, ILK has been shown to bind the Pinch 1 and 2 proteins (40), which in turn interact with Nck2, a SH2/SH3-containing adapter protein. Nck2 is present at cell adhesion sites and interacts with critical cytoskeleton-related signaling molecules including Wiskott-Aldrich syndrome protein and Pak (p21-activated serine/threonine kinase). Future studies must determine which of these ILK interactions are functionally relevant in terms of actin stability and focal adhesion formation specifically in endothelial cells.
Our studies with endothelium have also revealed alterations in phosphorylation of Akt on the activating phosphorylation site, Ser 473, but not in the basal phosphorylation state of GSK-3, Erk 1/2, c-Jun N-terminal kinase, or focal adhesion kinase. However, apoptosis was not rescued by a constitutive active Akt construct. It must be noted that other studies have shown abnormal Akt signaling in models of ILK deficiency that lead to direct effects on cell survival (37, 38). Undoubtedly, the conflicting results from these various studies reflect cell-specific ILK function in the face of diverse stimuli. Thus, conditional ILK deletion can now be employed to parse out ILK signaling in specific tissues and in specific physiological contexts. How abnormalities in integrin signaling independent of Akt signaling lead to mitochondrial or stress-induced apoptosis remains a subject for future studies.
Data from several groups, including our own, suggest that ILK may also be important in cell spreading and movement (8, 15, 42). Thus, abnormal endothelial chemotaxis may have also contributed to the vascular abnormalities we noted in intact organisms. The marked apoptosis we noted in vitro may have been abrogated somewhat in vivo by other prosurvival signals, and our data do not preclude multiple roles of ILK in endothelial cell biology. Interestingly, the patterning defects we observed in the developing zebra fish were restricted to specific regions of the vasculature, suggesting that heterogeneous mechanisms may regulate vascular development, perhaps presaging adult vessel heterogeneities. Variability of vessel abnormalities from ILK deletion was also observed in the mice. Such differential effects might reflect heterogeneity in the requirements for and consequences of endothelial integrin signaling in different vascular beds and may be confirmed in adults by temporally regulated, endothelium-restricted gene inactivation.
In summary, our genetic studies with two vertebrate organisms demonstrate a role for ILK in integrin-matrix interactions and endothelial cell survival. These pleiotropic effects clearly contribute in critical ways to endothelial cell and vascular development and may have important implications as well for vascular pathology.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
E.B.F. and E.L. contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Anton, M., and F. L. Graham. 1995. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69:4600-4606.[Abstract]
3. Bazzoni, G., D. T. Shih, C. A. Buck, and M. E. Hemler. 1995. Monoclonal antibody 9EG7 defines a novel beta 1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J. Biol. Chem. 270:25570-25577.
4. Brooks, P. C., R. A. Clark, and D. A. Cheresh. 1994. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571.
5. Brooks, P. C., A. M. Montgomery, M. Rosenfeld, R. A. Reisfeld, T. Hu, G. Klier, and D. A. Cheresh. 1994. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.[CrossRef][Medline]
6. Chavakis, E., and S. Dimmeler. 2002. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol. 22:887-893.
7. Cheresh, D. A., and D. G. Stupack. 2002. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat. Med. 8:193-194.[CrossRef][Medline]
8. Chun, S. J., M. N. Rasband, R. L. Sidman, A. A. Habib, and T. Vartanian. 2003. Integrin-linked kinase is required for laminin-2-induced oligodendrocyte cell spreading and CNS myelination. J. Cell Biol. 163:397-408.
9. Cross, L. M., M. A. Cook, S. Lin, J. N. Chen, and A. L. Rubinstein. 2003. Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler. Thromb. Vasc. Biol. 23:911-912.
10. Dai, D. L., N. Makretsov, E. I. Campos, C. Huang, Y. Zhou, D. Huntsman, M. Martinka, and G. Li. 2003. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin. Cancer Res. 9:4409-4414.
11. Dedhar, S. 2000. Cell-substrate interactions and signaling through ILK. Curr. Opin. Cell Biol. 12:250-256.[CrossRef][Medline]
12. Delcommenne, M., C. Tan, V. Gray, L. Rue, J. Woodgett, and S. Dedhar. 1998. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 95:11211-11216.
13. Drake, C. J., and P. A. Fleming. 2000. Vasculogenesis in the day 6.5 to 9.5 mouse embryo. Blood 95:1671-1679.
14. Friedlander, M., P. C. Brooks, R. W. Shaffer, C. M. Kincaid, J. A. Varner, and D. A. Cheresh. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500-1502.
15. Friedrich, E. B., S. Sinha, L. Li, S. Dedhar, T. Force, A. Rosenzweig, and R. E. Gerszten. 2002. Role of integrin-linked kinase in leukocyte recruitment. J. Biol. Chem. 277:16371-16375.
16. Gerritsen, M. E., C. P. Shen, W. J. Atkinson, R. C. Padgett, M. A. Gimbrone, Jr., and D. S. Milstone. 1996. Microvascular endothelial cells from E-selectin-deficient mice form tubes in vitro. Lab. Investig. 75:175-184.[Medline]
17. Gerritsen, M. E., C. P. Shen, M. C. McHugh, W. J. Atkinson, J. M. Kiely, D. S. Milstone, F. W. Luscinskas, and M. A. Gimbrone, Jr. 1995. Activation-dependent isolation and culture of murine pulmonary microvascular endothelium. Microcirculation 2:151-163.[Medline]
18. Gimbrone, M. A., Jr. 1999. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. Thromb. Haemostasis 82:722-726.[Medline]
19. Graff, J. R., J. A. Deddens, B. W. Konicek, B. M. Colligan, B. M. Hurst, H. W. Carter, and J. H. Carter. 2001. Integrin-linked kinase expression increases with prostate tumor grade. Clin. Cancer Res. 7:1987-1991.
20. Grashoff, C., A. Aszodi, T. Sakai, E. B. Hunziker, and R. Fassler. 2003. Integrin-linked kinase regulates chondrocyte shape and proliferation. EMBO Rep. 4:432-438.[CrossRef][Medline]
21. Gurtner, G. C., V. Davis, H. Li, M. J. McCoy, A. Sharpe, and M. I. Cybulsky. 1995. Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev. 9:1-14.
22. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.[CrossRef][Medline]
23. Hannigan, G. E., C. Leung-Hagesteijn, L. Fitz-Gibbon, M. G. Coppolino, G. Radeva, J. Filmus, J. C. Bell, and S. Dedhar. 1996. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96.[CrossRef][Medline]
24. Hynes, R. O. 2002. Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687.[CrossRef][Medline]
25. Koni, P. A., S. K. Joshi, U. A. Temann, D. Olson, L. Burkly, and R. A. Flavell. 2001. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J. Exp. Med. 193:741-754.
26. Lenter, M., H. Uhlig, A. Hamann, P. Jeno, B. Imhof, and D. Vestweber. 1993. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc. Natl. Acad. Sci. USA 90:9051-9055.
27. Mackinnon, A. C., H. Qadota, K. R. Norman, D. G. Moerman, and B. D. Williams. 2002. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Curr. Biol. 12:787-797.[CrossRef][Medline]
28. Maeshima, Y., M. Manfredi, C. Reimer, K. A. Holthaus, H. Hopfer, B. R. Chandamuri, S. Kharbanda, and R. Kalluri. 2001. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276:15240-15248.
29. Maeshima, Y., A. Sudhakar, J. C. Lively, K. Ueki, S. Kharbanda, C. R. Kahn, N. Sonenberg, R. O. Hynes, and R. Kalluri. 2002. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295:140-143.
30. Matsui, T., L. Li, F. del Monte, Y. Fukui, T. Franke, R. Hajjar, and A. Rosenzweig. 1999. Adenoviral gene transfer of activated PI 3-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100:2373-2379.
31. Nikolopoulos, S. N., and C. E. Turner. 2000. Actopaxin, a new focal adhesion protein that binds paxillin LD motifs and actin and regulates cell adhesion. J. Cell Biol. 151:1435-1448.
32. Persad, S., S. Attwell, V. Gray, M. Delcommenne, A. Troussard, J. Sanghera, and S. Dedhar. 2000. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl. Acad. Sci. USA 97:3207-3212.
33. Rossant, J., and J. C. Cross. 2001. Placental development: lessons from mouse mutants. Nat. Rev. Genet. 2:538-548.[Medline]
34. Sakai, T., S. Li, D. Docheva, C. Grashoff, K. Sakai, G. Kostka, A. Braun, A. Pfeifer, P. D. Yurchenco, and R. Fassler. 2003. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes Dev. 17:926-940.
35. Stupack, D. G., and D. A. Cheresh. 2002. Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci. 115:3729-3738.
36. Tan, C., S. Cruet-Hennequart, A. Troussard, L. Fazli, P. Costello, K. Sutton, J. Wheeler, M. Gleave, J. Sanghera, and S. Dedhar. 2004. Regulation of tumour angiogenesis by integrin linked kinase (ILK). Cancer Cell 5:79-90.
37. Terpstra, L., J. Prud'homme, A. Arabian, S. Takeda, G. Karsenty, S. Dedhar, and R. St-Arnaud. 2003. Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes. J. Cell Biol. 162:139-148.
38. Troussard, A. A., N. N. Mawji, C. Ong, A. Mui, R. St Arnaud, and S. Dedhar. 2003. Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J. Biol. Chem. 278:22374-22378.
39. Westerfield, M. 1993. The Zebrafish Book. University of Oregon Press, Eugene.
40. Wu, C. 1999. Integrin-linked kinase and PINCH: partners in regulation of cell-extracellular matrix interaction and signal transduction. J. Cell Sci. 112:4485-4489.[Abstract]
41. Wu, C., and S. Dedhar. 2001. Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J. Cell Biol. 155:505-510.
42. Zhang, Y., L. Guo, K. Chen, and C. Wu. 2002. A critical role of the PINCH-ILK interaction in the regulation of cell shape change and migration. J. Biol. Chem. 277:318-326.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|